DE10333835A1 - 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung - Google Patents

6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung Download PDF

Info

Publication number
DE10333835A1
DE10333835A1 DE10333835A DE10333835A DE10333835A1 DE 10333835 A1 DE10333835 A1 DE 10333835A1 DE 10333835 A DE10333835 A DE 10333835A DE 10333835 A DE10333835 A DE 10333835A DE 10333835 A1 DE10333835 A1 DE 10333835A1
Authority
DE
Germany
Prior art keywords
dimethylaminomethyl
diol
weight
cyclohexane
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10333835A
Other languages
German (de)
English (en)
Inventor
Johannes Bartholomaeus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE10333835A priority Critical patent/DE10333835A1/de
Priority to PCT/EP2004/008081 priority patent/WO2005009329A2/de
Priority to CA002533330A priority patent/CA2533330A1/en
Priority to EP04741158A priority patent/EP1648420A2/de
Priority to JP2006520768A priority patent/JP2006528604A/ja
Publication of DE10333835A1 publication Critical patent/DE10333835A1/de
Priority to US11/334,344 priority patent/US20060121113A1/en
Priority to US12/757,455 priority patent/US20100196473A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE10333835A 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung Ceased DE10333835A1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE10333835A DE10333835A1 (de) 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2004/008081 WO2005009329A2 (de) 2003-07-24 2004-07-20 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
CA002533330A CA2533330A1 (en) 2003-07-24 2004-07-20 Pharmaceutical preparation containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
EP04741158A EP1648420A2 (de) 2003-07-24 2004-07-20 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verz gerter wirkstofffreisetzun g
JP2006520768A JP2006528604A (ja) 2003-07-24 2004-07-20 ６−ジメチルアミノメチル−１−（３−メトキシ−フェニル）−シクロヘキサン−１，３−ジオールを含む、有効物質徐放性医薬
US11/334,344 US20060121113A1 (en) 2003-07-24 2006-01-19 Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US12/757,455 US20100196473A1 (en) 2003-07-24 2010-04-09 Pharmaceutical Composition Containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with Delayed Active Ingredient Release

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10333835A DE10333835A1 (de) 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
DE10333835A1 true DE10333835A1 (de) 2005-03-10

Family

ID=34088810

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10333835A Ceased DE10333835A1 (de) 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Country Status (6)

Country Link
US (2) US20060121113A1 (enExample)
EP (1) EP1648420A2 (enExample)
JP (1) JP2006528604A (enExample)
CA (1) CA2533330A1 (enExample)
DE (1) DE10333835A1 (enExample)
WO (1) WO2005009329A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010192A (es) * 2005-02-25 2007-09-07 Gruenenthal Chemie Formas cristalinas del clorhidrato de (1rs, 3rs, 6rs)-6-dimetilaminometil-1-(3-metoxi-fenil) ciclohexano-1, 3-diol.
DE102005009217A1 (de) * 2005-02-25 2006-08-31 Grünenthal GmbH Phosphatsalze der 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexanverbindungen
EP1695957A1 (en) * 2005-02-25 2006-08-30 Grünenthal GmbH Crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
DE102007022790A1 (de) * 2007-05-11 2008-11-20 Grünenthal GmbH Axomadol zur Schmerzbehandlung bei Arthrose
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
EP2085081A1 (de) * 2008-02-04 2009-08-05 Grünenthal GmbH 3-(2-Dimethylaminomethyl-cyclohexyl)-phenol gegen polyneuropathischen Schmerz
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
DE102008042603A1 (de) * 2008-10-06 2010-04-08 Biotronik Vi Patent Ag Implantat sowie Verfahren zur Herstellung einer degradationshemmenden Schicht auf einer Körperoberfläche eines Implantats
WO2011008298A2 (en) * 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
US20110053914A1 (en) 2009-08-28 2011-03-03 Gruenenthal Gmbh Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
EP2477960A1 (en) 2009-09-14 2012-07-25 Grünenthal GmbH Crystalline modifications of 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol
US20120022294A1 (en) 2010-06-30 2012-01-26 Gruenenthal Gmbh Axomadol or a Metabolite Thereof for Use in the Treatment of Irritable Bowel Syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4315525A1 (de) * 1993-05-10 1994-11-17 Euro Celtique Sa Pharmazeutische Zusammensetzung
EP0753506B1 (de) * 1995-07-11 1999-08-18 Grünenthal GmbH 6-Dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
DE10059413A1 (de) * 2000-11-30 2002-06-20 Gruenenthal Gmbh Verwendung von substituierten 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4315525A1 (de) * 1993-05-10 1994-11-17 Euro Celtique Sa Pharmazeutische Zusammensetzung
EP0753506B1 (de) * 1995-07-11 1999-08-18 Grünenthal GmbH 6-Dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe

Also Published As

Publication number Publication date
WO2005009329A2 (de) 2005-02-03
US20060121113A1 (en) 2006-06-08
CA2533330A1 (en) 2005-02-03
US20100196473A1 (en) 2010-08-05
EP1648420A2 (de) 2006-04-26
JP2006528604A (ja) 2006-12-21
WO2005009329A3 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
DE10333835A1 (de) 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
Kupsch et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
AU2016416435B2 (en) Liquid cleansing compositions with an antibacterial system and method of manufacturing thereof
Kehr et al. Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®
CA2369095C (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US20210093652A1 (en) Compositions and methods of potentiating antimicrobials
MY127797A (en) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
CA2832854C (en) Method of inhibiting harmful microorganisms and barrier-forming composition therefor
DE05852057T1 (de) Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
EP2263667A3 (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
DE19644998C1 (de) Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
DE4315525B4 (de) Pharmazeutische Zusammensetzung
DE60312874T2 (de) Kombinationstherapie mit verwendung eines serotonin-wiederaufnahmehemmers
US10426761B2 (en) Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
WO2014107572A1 (en) Body surface treatment composition and method
DE69713586T2 (de) Dosisformen und deren verwendungen
Cornbleet Discoid Lupus Erythematosus Treated with Plaguenil
RU2007102290A (ru) Способ лечения нарушений и заболеваний нервной системы
WO2006107593A3 (en) Matrix-based pulse release pharmaceutical formulation
DE102009013225A1 (de) Verwendung von Pflanzen der Gattung Sideritis und Extrakten daraus zur Behandlung des Aufmerksamkeitsdefizit-Hyperaktivitätssyndroms
CZ285681B6 (cs) Použití selegilinu pro výrobu farmacetického prostředku k ošetřování epileptických onemocnění a farmaceutický prostředek, který selegilin obsahuje
DE102015115876A1 (de) Substanz zur Prophylaxe und Behandlung von Infektionen durch Influenzaviren
DK181405B1 (en) Gel for Intranasal Application, its Provision and Use
HK40085288A (en) Combinations of cannabinoids and n-acylethanolamines

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final

Effective date: 20121005